Fig. 4.

Preexisting plasma levels of TGF-β predict the magnitude of AE37 vaccine-induced specific T-cell responses and clinical efficacy. See also legend to Fig. 3. Correlation between preexisting TGF-β levels and vaccine-induced immunity. a HLA-A*24+, e HLA-DRB1*11+, and i HLA-DRB1*11+/A*24+ patients with increased preexisting (filled circles) and low preexisting TGF-β levels (open circles). Levels of IFN-γ immunity (b, f, j) and DTH reactions c, g, k at the indicated time points for HLA-A*24, HLA- DRB1*11, and HLA-DRB1*11+/A*24+ patients, respectively. Correlation of TGF-β levels with OS for each group of patients from diagnosis (d, h, l)